GGrantIndex
← Leaderboards

Christopher A Maher

Washington University

$7,094,981
Attributed
$10,846,935
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.9M · FY201025
$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,846,935 · 9

By mechanism

R01$9,639,866 · 6
R00$684,518 · 1
R21$314,532 · 1
K99$208,019 · 1

Most similar at Washington University

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorCohortGenesTranscriptome SequencingMalignant NeoplasmsTissuesCancer TherapyNeoplasm MetastasisPhenotypeGene ExpressionMonitorTranslational ImpactCellsSamplingSiteInsightIn VivoIn VitroPrimary NeoplasmTherapeutic TargetCodeRegulationOncogenicTumor Biology

Grant awards (30)

Mechanism of acid signaling in bone organ metastases on tumor and myeloid cell evolution towards immune suppression and tumor progression$645,323
R01 · FY2025 · CA
Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer$633,122
R01 · FY2025 · CA · contact PI
Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer$610,019
R01 · FY2025 · CA · contact PI
The role of RAMS11 in colorectal cancer progression and treatment resistance$544,644
R01 · FY2025 · CA · contact PI
Understanding the role of RAMS11 in non small cell lung cancer$355,706
R01 · FY2025 · CA · contact PI
The role of RAMS11 in colorectal cancer progression and treatment resistance$85,153
R01 · FY2025 · CA · contact PI
Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer$608,488
R01 · FY2024 · CA · contact PI
Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer$596,475
R01 · FY2024 · CA · contact PI
The role of RAMS11 in colorectal cancer progression and treatment resistance$545,341
R01 · FY2024 · CA · contact PI
The role of RAMS11 in colorectal cancer progression and treatment resistance$85,153
R01 · FY2024 · CA · contact PI
Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer$636,570
R01 · FY2023 · CA · contact PI
The role of RAMS11 in colorectal cancer progression and treatment resistance$567,677
R01 · FY2023 · CA · contact PI
Molecular Biomarkers of Long-Term Response to Androgen Deprivation Therapy and Radiation in Prostate Cancer$673,467
R01 · FY2022 · CA · contact PI
The role of RAMS11 in colorectal cancer progression and treatment resistance$558,058
R01 · FY2022 · CA · contact PI
The role of RAMS11 in colorectal cancer progression and treatment resistance$551,689
R01 · FY2021 · CA · contact PI
THE ROLE OF POLYCOMB ASSOCIATED LONG NON-CODING RNAS IN LUNG CANCER METASTASIS$348,844
R01 · FY2021 · CA · contact PI
THE ROLE OF POLYCOMB ASSOCIATED LONG NON-CODING RNAS IN LUNG CANCER METASTASIS$348,844
R01 · FY2020 · CA · contact PI
THE ROLE OF POLYCOMB ASSOCIATED LONG NON-CODING RNAS IN LUNG CANCER METASTASIS$338,378
R01 · FY2019 · CA · contact PI
THE ROLE OF POLYCOMB ASSOCIATED LONG NON-CODING RNAS IN LUNG CANCER METASTASIS$91,156
R01 · FY2019 · CA · contact PI
THE ROLE OF POLYCOMB ASSOCIATED LONG NON-CODING RNAS IN LUNG CANCER METASTASIS$348,844
R01 · FY2018 · CA · contact PI
THE ROLE OF POLYCOMB ASSOCIATED LONG NON-CODING RNAS IN LUNG CANCER METASTASIS$93,177
R01 · FY2018 · CA · contact PI
THE ROLE OF POLYCOMB ASSOCIATED LONG NON-CODING RNAS IN LUNG CANCER METASTASIS$24,894
R01 · FY2018 · CA · contact PI
THE ROLE OF POLYCOMB ASSOCIATED LONG NON-CODING RNAS IN LUNG CANCER METASTASIS$348,844
R01 · FY2017 · CA · contact PI
CLONAL EVOLUTION OF STRUCTURAL VARIANTS IN THE PROGRESSION OF METASTATIC COLORECT$142,969
R21 · FY2015 · CA · contact PI
CLONAL EVOLUTION OF STRUCTURAL VARIANTS IN THE PROGRESSION OF METASTATIC COLORECT$171,563
R21 · FY2014 · CA · contact PI
Characterization of Cancer Transcriptomes using Next Generation Sequencing$211,158
R00 · FY2013 · CA · contact PI
Characterization of Cancer Transcriptomes using Next Generation Sequencing$231,830
R00 · FY2012 · CA · contact PI
Characterization of Cancer Transcriptomes using Next Generation Sequencing$241,530
R00 · FY2011 · CA · contact PI
Characterization of Cancer Transcriptomes using Next Generation Sequencing$105,068
K99 · FY2011 · CA · contact PI
Characterization of Cancer Transcriptomes using Next Generation Sequencing$102,951
K99 · FY2010 · CA · contact PI